研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]Anhui Provincial Cancer Hospital,Hefei,Anhui,China,230031[3]Beijing Tongren Hospital Affiliated to Capital Medical University,Beijing,Beijing,China,100005[4]Gansu Cancer Hospital,Lanzhou,Gansu,China,730050[5]Guangxi Zhuang Autonomous Region Cancer Hospital (Affiliated Cancer Hospital of Guangxi Medical University),Nanning,Guangxi,China,530021[6]The First Affiliated Hospital of Hebei North University,Shijiazhuang,Hebei,China,050051[7]Tianjin Cancer Hospital,Tianjin,Hebei,China,300181[8]Henan Cancer Hospital,Zhengzhou,Henan,China,450003[9]The First Affiliated Hospital of Zhengzhou University,Zhengzhou,Henan,China,450052[10]Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan,Hubei,China,430030[11]Hubei Cancer Hospital,Wuhan,Hubei,China,430079[12]Hunan Cancer Hospital,Changsha,Hunan,China,410031[13]Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University,Nanjing,Jiangsu,China,210008[14]Jiangsu North People''s Hospital,Yangzhou,Jiangsu,China,225003[15]Liaoning Cancer Hospital and Institute,Shenyang,Liaoning,China,110801[16]The First Affiliated Hospital of Xi''an Jiaotong University,Xi''an,Shanxi,China,710061[17]Shanxi Provincial Tumor Hospital,Xi''an,Shanxi,China,710065[18]Tianjin People''s Hospital,Tianjin,Tianjin,China,300122[19]The First Affiliated Hospital of Kunming Medical University,Kunming,Yunnan,China,650032[20]Zhejiang Provincial People''s Hospital,Hangzhou,Zhejiang,China,314408
研究目的：
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
